Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy.
about
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus.Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
P2860
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Lipid-lowering interventions t ...... ter in lipid-lowering therapy.
@en
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9
@nl
type
label
Lipid-lowering interventions t ...... ter in lipid-lowering therapy.
@en
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9
@nl
prefLabel
Lipid-lowering interventions t ...... ter in lipid-lowering therapy.
@en
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9
@nl
P2093
P2860
P356
P1433
P1476
Lipid-lowering interventions t ...... ter in lipid-lowering therapy.
@en
P2093
Constantine E Kosmas
Eddy DeJesus
Eliscer Guzman
Frank Garcia
Peter D Montan
Rosmery Morcelo
P2860
P304
P356
10.7573/DIC.212511
P577
2017-11-22T00:00:00Z